72
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Association of Serum Nonesterified Fatty Acids with Cardiovascular Event in Patients with Chronic Kidney Disease

ORCID Icon &
Pages 2033-2040 | Published online: 24 May 2021

References

  • Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038. doi:10.1001/jama.298.17.2038
  • Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67(6):2089–2100. doi:10.1111/j.1523-1755.2005.00365.x
  • Foundation, National Kidney. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2006;47(3):11–145.
  • Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2011;80(6):572–586. doi:10.1038/ki.2011.223
  • Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268(5):456–467. doi:10.1111/j.1365-2796.2010.02269.x
  • Christa M, Angela D, Hannelore L. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J. 2006;(10):1245.
  • Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl. 2008;74(Suppl. 111):S4–S9. doi:10.1038/ki.2008.516
  • Ruiz S, Pergola PE, Zager RA, et al. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 2013;83(6):1029–1041. doi:10.1038/ki.2012.439
  • Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol. 2010;298(3):F662–71. doi:10.1152/ajprenal.00421.2009
  • Stich V, Berlan M. Physiological regulation of NEFA availability: lipolysis pathway. Proc Nutr Soc. 2004;63(2):369–374. doi:10.1079/PNS2004350
  • Pilz S, März W. Free fatty acids as a cardiovascular risk factor. Clin Chem Lab Med. 2008;46(4):429–434. doi:10.1515/CCLM.2008.118
  • Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol. 2009;54(18):1637–1646. doi:10.1016/j.jacc.2009.07.024
  • Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997;46(1):3. doi:10.2337/diab.46.1.3
  • Roy VK, Kumar A, Joshi P, et al. Plasma free fatty acid concentrations as a marker for acute myocardial infarction. J Clin Diagn Res. 2013;7(11):2432–2434.
  • Pilz S, Scharnag H, Tiran B, et al. Mo-P1:118 free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. Atheroscler Suppl. 2006;7(3):72.
  • Pilz S, Scharnagl H, Tiran B. Elevated plasma free fatty acids predict sudden cardiac death: a 6.85-year follow-up of 3315 patients after coronary angiography. Eur Heart J. 2007;28(22):2763–2769. doi:10.1093/eurheartj/ehm343
  • Havmoeller R, Reinier K, Teodorescu C, et al. Elevated plasma free fatty acids are associated with sudden death: a prospective community-based evaluation at the time of cardiac arrest. Heart Rhythm. 2014;11(4):691–696. doi:10.1016/j.hrthm.2014.01.012
  • Jouven X, Charles MA, Desnos M, et al. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation. 2001;104(7):756–761. doi:10.1161/hc3201.094151
  • Marie AC, Annick F, Nadine T, et al. High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: results from the Paris Prospective Study. Am J Epidemiol. 2001;153(3):292–298.
  • Pirro M, Mauriège P, Tchernof A. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study. Atherosclerosis. 2002;160(2):377–384. doi:10.1016/S0021-9150(01)00588-3
  • Coresh J, Levey AS, Levin A, et al. Chronic kidney disease definition A stable definition of chronic kidney disease improves knowledge and patient care. BMJ. 2013;347(sep18 1):f5553. doi:10.1136/bmj.f5553
  • Stevens PE. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825. doi:10.7326/0003-4819-158-11-201306040-00007
  • Mozaffarian D. Free fatty acids, cardiovascular mortality, and cardiometabolic stress. Eur Heart J. 2007;28(22):2699–2700. doi:10.1093/eurheartj/ehm451
  • Zibo X, Xu H, Huang X. Nonesterified fatty acids and cardiovascular mortality in elderly men with CKD. Clin J Am Soc Nephrol. 2015;10(4):584–591. doi:10.2215/CJN.08830914
  • Wu Y, Zhou H, Wu K, et al. PTEN phosphorylation and nuclear export mediate free fatty acid-induced oxidative stress. Antioxid Redox Signal. 2014;20(9):1382–1395. doi:10.1089/ars.2013.5498
  • Boden G. Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes. 2011;18(2):139–143. doi:10.1097/MED.0b013e3283444b09
  • Oliver MF. Sudden cardiac death: the lost fatty acid hypothesis. QJM. 2006;99(10):701. doi:10.1093/qjmed/hcl084
  • Makiguchi M, Kawaguchi H, Tamura M, et al. Effect of palmitic acid and fatty acid binding protein on ventricular fibrillation threshold in the perfused rat heart. Cardiovasc Drugs Ther. 1991;5(4):753–761. doi:10.1007/BF03029751
  • Soloff LA. Arrhythmias following infusions of fatty acids. Am Heart J. 1970;80(5):671–674. doi:10.1016/0002-8703(70)90012-8
  • Shimabukuro M. [Insulin resistance and free fatty acid]. Nihon Rinsho. 2012;70(Suppl3):185–190. Japanese.
  • Djousse L, Biggs ML, Ix JH, et al. Nonesterified fatty acids and risk of sudden cardiac death in older adults. Circ Arrhythm Electrophysiol. 2012;5(2):273. doi:10.1161/CIRCEP.111.967661